Bioisosteric approach in designing new monastrol derivatives: An investigation on their ADMET prediction using in silico derived parameters
Tóm tắt
Từ khóa
Tài liệu tham khảo
Brown, 2006, On scaffolds and hopping in medicinal chemistry, Mini Rev. Med. Chem., 6, 1217, 10.2174/138955706778742768
Ertl, 2007, In silico identification of bioisosteric functional groups, Curr. Opin. Drug Discov. Devel., 10, 281
Wermuth, 2003, 189
Gunderson, 2002, Evolutionary conservation of microtubule-capture mechanisms, Nat. Rev. Mol. Cell Biol., 3, 296, 10.1038/nrm777
Sarli, 2008, Targeting the Kinesin spindle protein: basic principles and clinical implications, Clin. Cancer Res., 14, 7583, 10.1158/1078-0432.CCR-08-0120
Rowinski, 1993, Neurotoxicity of taxol, J. Natl. Cancer Inst., 15, 107
El-Nassan, 2013, Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents, Eur. J. Med. Chem., 62, 614, 10.1016/j.ejmech.2013.01.031
Mayer, 1999, Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype based screen, Science, 286, 971, 10.1126/science.286.5441.971
Maliga, 2002, Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5, Chem. Biol., 9, 989, 10.1016/S1074-5521(02)00212-0
Kapoor, 2000, Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5, J. Cell Biol., 150, 975, 10.1083/jcb.150.5.975
Schmidt, 2007, Mitotic drug targets and the development of novel anti-mitotic anticancer drugs, Drug Resist. Updat., 10, 162, 10.1016/j.drup.2007.06.003
Boobis, 2002, In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15, Eur. J. Pharm. Sci., 17, 183, 10.1016/S0928-0987(02)00185-9
Hou, 2006, Recent advances in computational prediction of drug absorption and permeability in drug discovery, Curr. Med. Chem., 13, 2653, 10.2174/092986706778201558
Hecht, 2009, Computational intelligence methods for ADMET prediction, Front. Drug Des. Discov., 4, 351
Moroy, 2012, Toward in silico structure-based ADMET prediction in drug discovery, Drug Discovery Today, 17, 44, 10.1016/j.drudis.2011.10.023
Hosea, 2013, Predicting pharmacokinetic profiles using in silico derived parameters, Mol. Pharm., 10, 1207, 10.1021/mp300482w
Rashid, 2013, Structure based virtual screening-driven identification of monastrol as a potent urease inhibitor, J. Mol. Graphics Modell., 43, 47, 10.1016/j.jmgm.2013.04.006
Rashid, 2013, Microwave assisted partial synthesis of enantiomerically pure S-ispinesib-A case study, J. Chem. Soc. Pak., 35, 846
Russowsky, 2006, Synthesis and differential antiproliferative activity of Biginelli compounds against cancer cell lines: monastrol, oxo-monastrol and oxygenated analogues, Bioorg. Chem., 34, 173, 10.1016/j.bioorg.2006.04.003
ADMET Predictor version 6, Simulations Plus, Inc. Lancaster, CA, USA. www.simulations-plus.com.
Dearden, 2006, In silico prediction of aqueous solubility, Expert Opin. Drug Discovery, 1, 31, 10.1517/17460441.1.1.31
Tetko, 2007, 381
Mannhold, 2008, Calculation of molecular lipophilicity: state of the art and comparison methods, J. Pharm. Sci., 98, 84
Oyarzabal, 2009, Optimizing the performance of in silico ADMET general models according to local requirements, J. Chem. Inf. Model., 49, 2572, 10.1021/ci900308u
Sydney, 2013, In silico modeling to predict drug-induced phospholipidosis, Toxicol. Appl. Pharmacol.
Makiko, 2010, In silico classification of major clearance pathways of drugs with their physiochemical parameters, Drug Metab. Dispos., 38, 1362, 10.1124/dmd.110.032789
Sarah, 2012, Provisional biopharmaceutical classification of some common herbs used in Western Medicine, Mol. Pharm., 9, 815, 10.1021/mp200162b
Kirchmair, 2012, Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics and mechanisms, J. Chem. Inf. Model., 52, 617, 10.1021/ci200542m
Mannhold, 2009, Calculation of molecular lipophilicity: state-of-the-art and comparison of log P methods on more than 96,000 compounds, J. Pharm. Sci., 98, 861, 10.1002/jps.21494
Lipinski, 2000, Drug-like properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Methods, 44, 235, 10.1016/S1056-8719(00)00107-6
Opera, 2001, Is there a difference between leads and drugs? A historical perspective, J. Chem. Inf. Comput. Sci., 41, 1308, 10.1021/ci010366a
Smith, 2010, Future targets and chemistry and ADME needs, metabolism, pharmacokinetics and toxicity of functional groups: impact of chemical building blocks on ADMET, Royal Soc. Chem., 507
Waring, 2009, Defining optimum lipophilicity and molecular weight ranges for drug candidates – molecular weight dependent lower log D limits based on permeability, Bioorg. Med. Chem. Lett., 19, 2844, 10.1016/j.bmcl.2009.03.109
Zhao, 2001, Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure–activity relationship (QSAR) with the Abraham descriptors, J. Pharm. Sci., 90, 749, 10.1002/jps.1031
Poulin, 2001, Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs, J. Pharm. Sci., 90, 436, 10.1002/1520-6017(200104)90:4<436::AID-JPS1002>3.0.CO;2-P
Smith, 2010, Metabolism, pharmacokinetics and toxicity of functional groups: impact of chemical building blocks on ADMET, Royal Soc. Chem., 78
Yang, 2012, Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for drug-like compounds, J. Med. Chem., 55, 3667, 10.1021/jm201548z
Smith, 2001
Waterbeemd, 2001, Lipophilicity in PK design: methyl, ethyl, futile, J. Comput. Aided Mol. Des., 15, 273, 10.1023/A:1008192010023
Hitchcock, 2012, Structral modification that alter the P-glycoprotein eflux properties of compounds, J. Med. Chem., 55, 4877, 10.1021/jm201136z
Kirchmair, 2013, How do metabolites differ from their parent molecules and how are they excreted?, J. Chem. Inf. Model., 53, 354, 10.1021/ci300487z
Proudfoot, 2005, The evolution of synthetic oral drug properties, Bioorg. Med. Chem. Lett., 15, 1087, 10.1016/j.bmcl.2004.12.024
Raub, 2006, P-glycoprotein recognition of substrates and circumvention through rational drug design, Mol. Pharm., 3, 3, 10.1021/mp0500871
Egan, 2010, Predicting ADME properties in drug discovery, 165
Pearlstein, 2003, Understanding the structure–activity relationship of the human ether-a-go-go-related gene cardiac K+ channel: a model for bad behaviour, J. Med. Chem., 46, 2017, 10.1021/jm0205651
2012
Jiang, 2007, Docking studies on kinesin spindle protein inhibitors: an important cooperative ‘minor binding pocket’ which increases the binding affinity significantly, J. Mol. Model., 13, 987, 10.1007/s00894-007-0219-2